1. Scrip
  2. >>Business
  3. >>Deals

After Jounce, Concentra Pounces On Atea

COVID-19 Antiviral Firm Could Be Snapped Up

 
• By Kevin Grogan

Concentra's unsolicited bid for Atea is the latest proof that promising but financially strapped biotechs that are trading below cash are prime M&A targets.

Cat
• Source: Shutterstock

Having jumped in front of the UK's Redx Pharma Plc to snap up Jounce Therapeutics, Inc., Concerta Biosciences is looking to bag another embattled biotech, making a bid for the US antiviral specialist Atea Pharmaceuticals, Inc..

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.

Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal

 
• By Sushmita Panda

After dropping its lead program in December, Spruce has been exploring strategic options – and thinks it has a de-risked path for MPS IIIB therapy tralesinidase from BioMarin.

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome

 
• By Joseph Haas

Plus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

More from Business

China’s Biotech Stocks Proved More Resilient Than US’s Amid Market Turmoil

 
• By Andrew McConaghie, Edwin Elmhirst, and Dexter Jie Yan

Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.

Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal

 
• By Sushmita Panda

After dropping its lead program in December, Spruce has been exploring strategic options – and thinks it has a de-risked path for MPS IIIB therapy tralesinidase from BioMarin.

Finance Watch: Biopharma Sees An Early April VC Mega-Round Surge

 
• By Mandy Jackson

Private Company Edition: After Q1 venture capital investment slumped relative to 2024 totals due to declines in both smaller financings and mega-rounds, Q2 started off with six $100m-plus financings in the first half of April after there were only three in February and six in all off March.